295 related articles for article (PubMed ID: 23068431)
1. Multisteric TRPV1 nocisensor: a target for analgesics.
Szolcsányi J; Sándor Z
Trends Pharmacol Sci; 2012 Dec; 33(12):646-55. PubMed ID: 23068431
[TBL] [Abstract][Full Text] [Related]
2. Transient receptor potential vanilloid 1 as a therapeutic target in analgesia.
Szolcsányi J; Pintér E
Expert Opin Ther Targets; 2013 Jun; 17(6):641-57. PubMed ID: 23421411
[TBL] [Abstract][Full Text] [Related]
3. Capsaicin and sensory neurones: a historical perspective.
Szolcsányi J
Prog Drug Res; 2014; 68():1-37. PubMed ID: 24941663
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks.
Wong GY; Gavva NR
Brain Res Rev; 2009 Apr; 60(1):267-77. PubMed ID: 19150372
[TBL] [Abstract][Full Text] [Related]
5. TRPV1b overexpression negatively regulates TRPV1 responsiveness to capsaicin, heat and low pH in HEK293 cells.
Vos MH; Neelands TR; McDonald HA; Choi W; Kroeger PE; Puttfarcken PS; Faltynek CR; Moreland RB; Han P
J Neurochem; 2006 Nov; 99(4):1088-102. PubMed ID: 17018028
[TBL] [Abstract][Full Text] [Related]
6. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of TRPV channel block on polymodal activation of rat cutaneous nociceptors in vitro.
St Pierre M; Reeh PW; Zimmermann K
Exp Brain Res; 2009 Jun; 196(1):31-44. PubMed ID: 19404626
[TBL] [Abstract][Full Text] [Related]
8. TRPV1 signaling: mechanistic understanding and therapeutic potential.
Xia R; Samad TA; Btesh J; Jiang LH; Kays I; Stjernborg L; Dekker N
Curr Top Med Chem; 2011; 11(17):2180-91. PubMed ID: 21671876
[TBL] [Abstract][Full Text] [Related]
9. Hot target on nociceptors: perspectives, caveats and unique features.
Szolcsányi J
Br J Pharmacol; 2008 Dec; 155(8):1142-4. PubMed ID: 18997812
[TBL] [Abstract][Full Text] [Related]
10. TRPV1-Targeted Drugs in Development for Human Pain Conditions.
Iftinca M; Defaye M; Altier C
Drugs; 2021 Jan; 81(1):7-27. PubMed ID: 33165872
[TBL] [Abstract][Full Text] [Related]
11. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia.
Honore P; Chandran P; Hernandez G; Gauvin DM; Mikusa JP; Zhong C; Joshi SK; Ghilardi JR; Sevcik MA; Fryer RM; Segreti JA; Banfor PN; Marsh K; Neelands T; Bayburt E; Daanen JF; Gomtsyan A; Lee CH; Kort ME; Reilly RM; Surowy CS; Kym PR; Mantyh PW; Sullivan JP; Jarvis MF; Faltynek CR
Pain; 2009 Mar; 142(1-2):27-35. PubMed ID: 19135797
[TBL] [Abstract][Full Text] [Related]
12. Capsaicin receptor: TRPV1 a promiscuous TRP channel.
Pingle SC; Matta JA; Ahern GP
Handb Exp Pharmacol; 2007; (179):155-71. PubMed ID: 17217056
[TBL] [Abstract][Full Text] [Related]
13. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
[TBL] [Abstract][Full Text] [Related]
14. Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).
Lee Y; Hong S; Cui M; Sharma PK; Lee J; Choi S
Expert Opin Ther Pat; 2015 Mar; 25(3):291-318. PubMed ID: 25666693
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
[TBL] [Abstract][Full Text] [Related]
16. Transient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Voight EA; Kort ME
Expert Opin Ther Pat; 2010 Sep; 20(9):1107-22. PubMed ID: 20586701
[TBL] [Abstract][Full Text] [Related]
17. Forty years in capsaicin research for sensory pharmacology and physiology.
Szolcsányi J
Neuropeptides; 2004 Dec; 38(6):377-84. PubMed ID: 15567473
[TBL] [Abstract][Full Text] [Related]
18. Novel gating and sensitizing mechanism of capsaicin receptor (TRPV1): tonic inhibitory regulation of extracellular sodium through the external protonation sites on TRPV1.
Ohta T; Imagawa T; Ito S
J Biol Chem; 2008 Apr; 283(14):9377-87. PubMed ID: 18230619
[TBL] [Abstract][Full Text] [Related]
19. Polymodal Transient Receptor Potential Vanilloid Type 1 Nocisensor: Structure, Modulators, and Therapeutic Applications.
Cui M; Gosu V; Basith S; Hong S; Choi S
Adv Protein Chem Struct Biol; 2016; 104():81-125. PubMed ID: 27038373
[TBL] [Abstract][Full Text] [Related]
20. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
